Clinical Trials

885 enrolled

Stomach Neoplasms

NCT04680988 2025-08-05

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

194 enrolled

Gynecologic

Uterine Cervical Neoplasms, Recurrence

NCT05156970 2025-07-31

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

81 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04625803 2025-06-17

Neoadjuvant Therapy for Locally Advanced Colon Cancer

64 enrolled 11 charts

Colonic Neoplasms

NCT04195828 2025-04-01

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

106 enrolled

Advanced Gastric Cancer

NCT04649476 2025-01-10

NEOPBOSCC

68 enrolled 16 charts

Squamous Cell Carcinoma of Head and Neck

NCT05355168 2024-12-31

Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma

35 enrolled

Esophageal Squamous Cell Carcinoma, Drug-Related Side Effects and Adverse Reactions

NCT03878472 2024-12-16

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

25 enrolled

Stomach Neoplasms

NCT05003700 2024-11-05

Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma

39 enrolled

Carcinoma, Hepatocellular

NCT03417895 2024-08-07

PASSION

59 enrolled 17 charts

Thoracic

Small Cell Lung Carcinoma

NCT06376773 2024-04-19

Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.

Completed

234 enrolled

Advanced Gastric Cancer

NCT04613674 2024-03-27

A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

441 enrolled

Triple Negative Breast Neoplasms

NCT03558191 2024-03-15

SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.

156 enrolled 13 charts

Nasopharyngeal Carcinoma

NCT04627012 2024-03-06

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Completed

600 enrolled

Carcinoma, Hepatocellular, Liver Diseases

NCT04694183 2024-02-07

The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer

37 enrolled

Neoplasm Metastasis, Stomach Neoplasms

NCT03764293 2024-02-06

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

543 enrolled 13 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT03155425 2024-02-01

PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma

75 enrolled 10 charts

Lymphoid

Hodgkin Disease

NCT04720131 2024-01-30

Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

28 enrolled

Biliary Tract Neoplasms

NCT03099382 2024-01-22

Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

457 enrolled 9 charts

Esophageal Neoplasms

NCT03472365 2024-01-11

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

67 enrolled 12 charts

Stomach Neoplasms

NCT04805736 2024-01-05

Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer

60 enrolled

Breast Neoplasms

NCT04393506 2023-11-22

Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

21 enrolled

Mouth Neoplasms

NCT04346381 2023-09-18

Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor

233 enrolled

Other solid neoplasm

Solid Tumor

NCT05809336 2023-04-12

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

Phase 2/3 Completed

172 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT02721589 2023-02-28

A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects

126 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT02742935 2023-02-27

A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects

99 enrolled

BreastGastrointestinal

Breast Neoplasms, Gastrointestinal Neoplasms

NCT03755440 2022-09-21

PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.

6 enrolled

Stomach Neoplasms

NCT03945604 2022-08-12

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

32 enrolled

Triple Negative Breast Neoplasms

NCT03121716 2022-07-12

A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects

23 enrolled

Nasopharyngeal Carcinoma

NCT04047017 2021-07-30

GTN

20 enrolled

Gynecologic

Recurrence, Gestational Trophoblastic Disease

NCT04642664 2021-06-03

ACABC

22 enrolled

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT03394287 2020-10-23

A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC

40 enrolled

Breast Neoplasms

NCT03187314 2020-08-17

Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer

25 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Diseases, Esophageal Neoplasms

NCT03222440 2019-12-04

Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC

Phase NA Completed

20 enrolled

Esophageal Neoplasms

NCT02492789 2019-09-30

A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients